Clinical Trial Update: CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study [Phase 1]

View source ↗

Summary

Phase 1 PK/PD study of BIIB021 (CNF2024) in combination with Herceptin for breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BIIB021 (CNF2024) (BIIB021)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Biogen | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED